Pappas Capital LLC
09/02/2015 | Press release | Archived content
TESARO Announces U.S. FDA Approval of VARUBI™ (rolapitant)...
News | 09. 02. 2015
TESARO
Waltham, Mass., Sept. 2, 2015 - TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved VARUBI™ (rolapitant) in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.
Pappas Capital LLC published this content on September 02, 2015, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 22, 2026 at 10:01 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]